FindTrial
Sign In

NEO-PV-01

BIOLOGICAL3 trials

Sponsors

BioNTech US Inc.

Conditions

Bladder TumorsCarcinoma, Non-Small-Cell LungLung CancerMalignant MelanomaMelanomaMetastatic MelanomaNonsquamous Nonsmall Cell Neoplasm of LungSkin Cancer

Phase 1

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
CompletedNCT02897765
BioNTech US Inc.Bladder Tumors, Carcinoma, Non-Small-Cell Lung, Lung Cancer +5
Start: 2016-10-31End: 2020-05-31Updated: 2021-02-25
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
CompletedNCT03380871
BioNTech US Inc.Carcinoma, Non-Small-Cell Lung, Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung
Start: 2018-05-04End: 2021-02-05Updated: 2021-02-26
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
TerminatedNCT03597282
BioNTech US Inc.Metastatic Melanoma
Start: 2018-10-08End: 2020-08-11Updated: 2020-09-03

Related Papers

Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy
Frontiers in Immunology2022-09-2926 citations
Abstract 73: A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first-line non-squamous NSCLC: Associations with clinical outcomes
Cancer Research2021-07-014 citations
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
2021-06-0634 citations
364 A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC
Regular and Young Investigator Award Abstracts2020-11-01
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
2020-10-01521 citations
Abstract 942: The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes
Cancer Research2019-07-018 citations
Abstract 5006: Comprehensive gene expression analysis of the tumor microenvironment in patients with advanced cancer treated with a personalized neoantigen vaccine, NEO-PV-01, in combination with anti-PD1
Clinical Research (Excluding Clinical Trials)2019-07-011 citations
Abstract 5006: Comprehensive gene expression analysis of the tumor microenvironment in patients with advanced cancer treated with a personalized neoantigen vaccine, NEO-PV-01, in combination with anti-PD1
Cancer Research2019-07-011 citations
Abstract 942: The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes
Clinical Research (Excluding Clinical Trials)2019-07-01
A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer
Annals of Oncology2018-10-0123 citations
Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad <i>de novo</i> anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer
Cancer Research2018-07-019 citations
Abstract LB-147: Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study
Cancer Research2018-07-01
An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Journal of Clinical Oncology2018-05-205 citations
An open-label, phase Ib study of NEO-PV-01 + adjuvant with nivolumab in patients with melanoma, non-small cell lung carcinoma, or transitional cell carcinoma of the bladder.
Journal of Clinical Oncology2017-05-202 citations